CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use
Expert Review of Clinical Pharmacology · 2026
DOI: 10.1080/17512433.2026.2626454 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Han Minh Thuy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Environmental and Preventive Medicine, Oita University, Yufu, Japan. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Cytochrome P-450 CYP2C19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 136 Literaturangaben. Gefördert von: Grant-in-Aid for Scientific Research in Japan.
Abstract (Originalsprache)
Introduction Proton pump inhibitors (PPIs) are widely used to treat acid-related disorders; however, treatment response varies significantly due to Cytochrome P450 2C19 (CYP2C19) genetic polymorphisms that alter individual drug metabolism. Such variation can lead to insufficient acid suppression, resulting in treatment failure or adverse events. Genotype-guided PPI therapy represents an important step toward personalized gastroenterology by optimizing drug efficacy and safety.Areas covered This review summarizes evidence from clinical trials and meta-analyses examining CYP2C19-mediated differences in the pharmacokinetics and pharmacodynamics of PPIs in both adults and children. Relevant literature was identified primarily through PubMed and clinical guidelines, covering publications from 1989 to 2025. The review focuses on outcomes related to gastroesophageal reflux disease (GERD), Helicobacter pylori eradication, and eosinophilic esophagitis. Current trials indicate that genotype-guided, tailored PPI therapy – through dose adjustment, drug selection, or regimen modification – can improve treatment efficacy and control abdominal symptoms without increasing safety risks or costs.Expert opinion CYP2C19 genotype-guided therapy constitutes a practical approach to personalized medicine for acid-related disorders. Barriers to widespread implementation include limited test availability, uncertain cost-effectiveness, and insufficient clinician awareness. Future directions include integrating multi-gene pharmacogenomic testing, model-informed dosing, and artificial intelligence-based decision support to advance individualized acid suppression and personalized gastroenterology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Environmental and Preventive Medicine, Oita University, Yufu, Japan.
- Department of Basic Sciences in Medicine and Pharmacy, University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam.
- Division of Genome-Wide Infectious Microbiology, Research Center for GLOBAL and LOCAL Infectious Disease, Oita University, Yufu, Japan.
- Department of Gastrointestinal Tract Diseases, 108 Military Central Hospital, Hanoi, Vietnam.
- Department of Medicine, Gastroenterology and Hepatology Section, Baylor College of Medicine, Houston, TX, USA.
ORCID-Profile: Mitsushige Sugimoto
Förderung
- Grant-in-Aid for Scientific Research in Japan
Zitieren
APA
Thuy, H. M., Sugimoto, M., Quang, P. M. N., & Yamaoka, Y. (2026). CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2626454
Vancouver
Thuy HM, Sugimoto M, Quang PMN, Yamaoka Y. CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2626454
BibTeX
@article{Thuy2026,
author = {Thuy, Han Minh and Sugimoto, Mitsushige and Quang, Pham Minh Ngoc and Yamaoka, Yoshio},
title = {CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use},
journal = {Expert Review of Clinical Pharmacology},
year = {2026},
doi = {10.1080/17512433.2026.2626454}
}
EUVIMED